Grade: Pharmaceutical Grade

Factory Location: Quanzhou

Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East,Africa

Sample Provided: no

Payment Terms: L/C

Sopagliflozin LX-4211 is a dual inhibitor of SGLT1/SGLT2 and has a brand-new hypoglycemic mechanism. Existing studies have proved that it is effective for both type 1 diabetes and type 2 diabetes. In three key multicenter Phase III clinical studies of sopagliflozin as an insulin-adjuvant therapy for type 1 diabetes, the sopagliflozin group achieved the trial endpoints in all cases, and no severe hypoglycemia or other SAEs occurred during the study period.

This provides a clinical basis for the approval of sopagliflozin as an insulin-adjuvant therapy for type 1 diabetes. Sopigliflozin LX-4211 is a new oral diabetes drug jointly developed by Sanofi and Lescon Pharmaceuticals. As a dual inhibitor of SGLT-1 and SGLT-2, this drug can reduce postprandial blood glucose, increase GLP-1 and promote the excretion of urine sugar.